Display options
Cite
Murali R, Greene MI. Structure based antibody-like peptidomimetics. Pharmaceuticals (Basel). 2012;5(2):209-35doi: 10.3390/ph5020209.
Murali, R., & Greene, M. I. (2012). Structure based antibody-like peptidomimetics. Pharmaceuticals (Basel, Switzerland), 5(2), 209-35. https://doi.org/10.3390/ph5020209
Murali, Ramachandran, and Greene, Mark I. "Structure based antibody-like peptidomimetics." Pharmaceuticals (Basel, Switzerland) vol. 5,2 (2012): 209-35. doi: https://doi.org/10.3390/ph5020209
Murali R, Greene MI. Structure based antibody-like peptidomimetics. Pharmaceuticals (Basel). 2012 Feb 16;5(2):209-35. doi: 10.3390/ph5020209. PMID: 24288089; PMCID: PMC3763629.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2012 Feb 16;5(2):209-35. doi: 10.3390/ph5020209.

Structure based antibody-like peptidomimetics.

Pharmaceuticals (Basel, Switzerland)

Ramachandran Murali, Mark I Greene

Affiliations

  1. Department of Biomedical Sciences, Cedars-Sinai Medical Center, D5091 Davis Building, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. [email protected].

PMID: 24288089 PMCID: PMC3763629 DOI: 10.3390/ph5020209

Abstract

Biologics such as monoclonal antibodies (mAb) and soluble receptors represent new classes of therapeutic agents for treatment of several diseases. High affinity and high specificity biologics can be utilized for variety of clinical purposes. Monoclonal antibodies have been used as diagnostic agents when coupled with radionuclide, immune modulatory agents or in the treatment of cancers. Among other limitations of using large molecules for therapy the actual cost of biologics has become an issue. There is an effort among chemists and biologists to reduce the size of biologics which includes monoclonal antibodies and receptors without a reduction of biological efficacy. Single chain antibody, camel antibodies, Fv fragments are examples of this type of deconstructive process. Small high-affinity peptides have been identified using phage screening. Our laboratory used a structure-based approach to develop small-size peptidomimetics from the three-dimensional structure of proteins with immunoglobulin folds as exemplified by CD4 and antibodies. Peptides derived either from the receptor or their cognate ligand mimics the functions of the parental macromolecule. These constrained peptides not only provide a platform for developing small molecule drugs, but also provide insight into the atomic features of protein-protein interactions. A general overview of the reduction of monoclonal antibodies to small exocyclic peptide and its prospects as a useful diagnostic and as a drug in the treatment of cancer are discussed.

References

  1. Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6599-604 - PubMed
  2. Nat Biotechnol. 1998 Feb;16(2):153-7 - PubMed
  3. Trends Biotechnol. 1990 Sep;8(9):249-55 - PubMed
  4. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2550-3 - PubMed
  5. Nature. 1989 Dec 21-28;342(6252):877-83 - PubMed
  6. Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1089-93 - PubMed
  7. Biochemistry. 1994 Mar 22;33(11):3296-303 - PubMed
  8. Nature. 1991 Jan 24;349(6307):293-9 - PubMed
  9. Cancer Res. 1992 Jun 15;52(12):3402-8 - PubMed
  10. Methods Enzymol. 1991;198:272-7 - PubMed
  11. Mol Cell Biol. 1987 May;7(5):2019-23 - PubMed
  12. Nature. 1975 Aug 7;256(5517):495-7 - PubMed
  13. J Neuroimmunol. 1993 Jul;46(1-2):235-43 - PubMed
  14. Trends Biotechnol. 1993 Jul;11(7):301-5 - PubMed
  15. Ann Inst Pasteur Immunol (1985). 1985 Nov-Dec;136D(3):259-69 - PubMed
  16. Science. 1987 Jul 10;237(4811):178-82 - PubMed
  17. J Immunol. 1990 Feb 15;144(4):1375-81 - PubMed
  18. J Mol Biol. 1994 Sep 30;242(4):309-20 - PubMed
  19. Science. 1983 Feb 11;219(4585):632-7 - PubMed
  20. Ann Biol Clin (Paris). 1989;47(10):575-81 - PubMed
  21. Science. 1987 Jan 9;235(4785):177-82 - PubMed
  22. J Mol Biol. 2008 Feb 22;376(3):786-97 - PubMed
  23. Cancer Res. 1990 Mar 1;50(5):1550-8 - PubMed
  24. Cancer Res. 2006 Apr 1;66(7):3764-72 - PubMed
  25. Semin Nucl Med. 2010 May;40(3):167-81 - PubMed
  26. Postgrad Med. 1999 Oct 1;106(4):82-5, 88-90, 92 - PubMed
  27. Biochem J. 1994 Aug 15;302 ( Pt 1):73-9 - PubMed
  28. Biochem Biophys Res Commun. 2003 Jul 18;307(1):198-205 - PubMed
  29. Semin Oncol. 1999 Aug;26(4 Suppl 12):60-70 - PubMed
  30. Transplantation. 1994 Mar 27;57(6):788-93 - PubMed
  31. Pathobiology. 1991;59(1):46-52 - PubMed
  32. Exp Mol Pathol. 2002 Oct;73(2):93-103 - PubMed
  33. J Biol Chem. 1992 Mar 25;267(9):5977-84 - PubMed
  34. Nat Biotechnol. 1997 Feb;15(2):150-4 - PubMed
  35. Curr Opin Biotechnol. 1997 Aug;8(4):435-41 - PubMed
  36. Science. 1991 Jun 21;252(5013):1657-62 - PubMed
  37. Curr Opin Biotechnol. 1996 Dec;7(6):622-8 - PubMed
  38. Proc Natl Acad Sci U S A. 1985 Mar;82(5):1494-8 - PubMed
  39. Structure. 1999 Apr 15;7(4):361-70 - PubMed
  40. Mol Immunol. 1990 Jun;27(6):513-22 - PubMed
  41. Protein Eng. 2000 Aug;13(8):565-74 - PubMed
  42. Structure. 1994 Aug 15;2(8):733-46 - PubMed
  43. Curr Opin Immunol. 1999 Oct;11(5):548-57 - PubMed
  44. Nat Med. 2006 Apr;12(4):473-7 - PubMed
  45. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9129-33 - PubMed
  46. J Immunol. 1998 Aug 15;161(4):1829-36 - PubMed
  47. Nature. 2003 Feb 13;421(6924):756-60 - PubMed
  48. Nat Biotechnol. 1997 Nov;15(12):1266-70 - PubMed
  49. DNA Cell Biol. 2005 Jun;24(6):350-8 - PubMed
  50. J Mol Biol. 1993 Dec 5;234(3):897-901 - PubMed
  51. Int J Immunopharmacol. 1992 Apr;14(3):391-7 - PubMed
  52. Mol Cell. 2003 May;11(5):1151-62 - PubMed
  53. Trends Biotechnol. 1994 May;12(5):199-206 - PubMed
  54. Nature. 1984 Dec 6-12;312(5994):545-8 - PubMed
  55. Front Biosci. 2008 Jan 01;13:1619-33 - PubMed
  56. MAbs. 2010 Jan-Feb;2(1):77-83 - PubMed
  57. Breast Cancer. 2008;15(1):65-72 - PubMed
  58. AIDS Res Hum Retroviruses. 1993 Aug;9(8):733-40 - PubMed
  59. Nat Biotechnol. 1996 Apr;14(4):472-5 - PubMed
  60. Biochemistry. 1998 Sep 15;37(37):12918-26 - PubMed
  61. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6488-92 - PubMed
  62. J Immunol. 1989 Jun 15;142(12):4392-400 - PubMed
  63. Science. 2000 Feb 18;287(5456):1279-83 - PubMed
  64. Int J Cancer Suppl. 1990;5:55-61 - PubMed
  65. Curr Opin Chem Biol. 2005 Dec;9(6):627-31 - PubMed
  66. Cell. 1985 Jul;41(3):697-706 - PubMed
  67. Oncogene. 1989 Jan;4(1):81-8 - PubMed
  68. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10638-42 - PubMed
  69. J Cell Biochem. 1985;28(1):69-78 - PubMed
  70. Biochemistry. 2000 Feb 15;39(6):1217-22 - PubMed
  71. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10643-7 - PubMed
  72. Methods. 2008 Sep;46(1):25-32 - PubMed
  73. Trends Pharmacol Sci. 1996 Dec;17(12):450-6 - PubMed
  74. Curr Drug Saf. 2010 Oct;5(4):275-86 - PubMed
  75. Biochem Biophys Res Commun. 1984 Sep 17;123(2):797-802 - PubMed
  76. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18336-41 - PubMed
  77. Trends Biotechnol. 1996 May;14(5):153-8 - PubMed
  78. J Biol Chem. 2002 Aug 2;277(31):28330-9 - PubMed
  79. Science. 1989 May 12;244(4905):707-12 - PubMed
  80. Protein Eng. 1991 Oct;4(7):773-83 - PubMed
  81. Curr Opin Mol Ther. 2010 Apr;12(2):176-83 - PubMed
  82. Science. 1988 May 20;240(4855):1034-6 - PubMed
  83. Expert Opin Investig Drugs. 2007 May;16(5):595-604 - PubMed
  84. J Biol Chem. 2011 Apr 15;286(15):13612-25 - PubMed
  85. Protein Cell. 2010 Apr;1(4):319-330 - PubMed
  86. Mol Cancer Ther. 2009 Jan;8(1):185-93 - PubMed
  87. Biochem Soc Trans. 2009 Aug;37(Pt 4):751-5 - PubMed
  88. Curr Opin Biotechnol. 2011 Dec;22(6):843-8 - PubMed
  89. Curr Drug Saf. 2010 Oct;5(4):293-307 - PubMed
  90. J Immunol. 1983 Nov;131(5):2533-8 - PubMed
  91. J Biosci Bioeng. 2010 Aug;110(2):250-3 - PubMed
  92. Exp Mol Pathol. 1999 Sep;67(1):15-25 - PubMed
  93. Mol Cell Biol. 1989 Mar;9(3):1165-72 - PubMed
  94. Proc Natl Acad Sci U S A. 2010 Nov 23;107(47):20281-6 - PubMed
  95. Hum Gene Ther. 1994 Jul;5(7):809-20 - PubMed
  96. Protein Eng. 1999 Jul;12(7):563-71 - PubMed
  97. Cancer Biol Ther. 2004 Apr;3(4):361-70 - PubMed
  98. MAbs. 2011 Sep-Oct;3(5):415-6 - PubMed
  99. Protein Eng. 1996 Oct;9(10):895-904 - PubMed
  100. J Mol Biol. 1996 Oct 11;262(5):732-45 - PubMed
  101. Science. 1996 Jul 26;273(5274):458-64 - PubMed
  102. PLoS Pathog. 2009 Nov;5(11):e1000481 - PubMed
  103. Cancer Res. 1990 Aug 15;50(16):5184-7 - PubMed
  104. J Immunol. 1999 Mar 15;162(6):3663-71 - PubMed
  105. Proc Natl Acad Sci U S A. 1992 May 15;89(10):4285-9 - PubMed
  106. Dev Biol Stand. 1996;87:283-91 - PubMed
  107. J Mol Biol. 1977 May 25;112(3):535-42 - PubMed
  108. IDrugs. 2010 Aug;13(8):543-9 - PubMed
  109. J Biol Chem. 1991 Mar 15;266(8):5182-90 - PubMed
  110. J Natl Cancer Inst. 1990 Jul 18;82(14):1191-7 - PubMed
  111. FASEB J. 1995 Jan;9(1):73-80 - PubMed
  112. Cell. 1983 Dec;35(3 Pt 2):859-63 - PubMed
  113. Science. 1992 Feb 21;255(5047):959-65 - PubMed
  114. Cancer. 1999 Apr 15;85(8):1828-42 - PubMed
  115. Oncogene. 2006 Dec 14;25(59):7740-6 - PubMed
  116. EMBO J. 1994 May 15;13(10):2247-56 - PubMed
  117. Eur J Biochem. 1994 Apr 1;221(1):151-7 - PubMed
  118. Protein Sci. 1998 Feb;7(2):243-53 - PubMed
  119. J Med Chem. 2000 Jun 1;43(11):2135-48 - PubMed
  120. Biopolymers. 1993 Jul;33(7):1073-82 - PubMed
  121. Cancer Res. 1994 Dec 1;54(23):6176-85 - PubMed
  122. Nat Biotechnol. 1998 Mar;16(3):267-70 - PubMed
  123. Curr Opin Struct Biol. 2000 Aug;10(4):417-20 - PubMed
  124. Semin Oncol. 2002 Jun;29(3 Suppl 11):22-8 - PubMed
  125. Science. 1991 Aug 16;253(5021):792-5 - PubMed
  126. J Exp Med. 1988 Jun 1;167(6):1841-8 - PubMed
  127. Pathobiology. 1990;58(6):297-303 - PubMed
  128. J Mol Recognit. 1994 Mar;7(1):9-24 - PubMed
  129. J Immunol. 1985 Aug;135(2):1530-5 - PubMed
  130. J Med Chem. 2001 Aug 2;44(16):2565-74 - PubMed
  131. Int Rev Immunol. 1993;10(2-3):195-217 - PubMed
  132. Pharm Res. 1996 Jun;13(6):820-31 - PubMed
  133. Science. 1985 Sep 6;229(4717):974-6 - PubMed
  134. Immunol Invest. 2011;40(3):299-338 - PubMed
  135. J Exp Med. 1984 May 1;159(5):1502-11 - PubMed
  136. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1266-70 - PubMed
  137. Philos Trans R Soc Lond B Biol Sci. 1975 Nov 6;272(915):43-51 - PubMed
  138. Biopolymers. 1998;47(1):93-100 - PubMed
  139. Immunol Res. 1998;17(1-2):163-9 - PubMed
  140. Hematol Oncol Clin North Am. 1995 Apr;9(2):475-506 - PubMed
  141. Bioorg Med Chem. 1994 Sep;2(9):999-1006 - PubMed
  142. Immunol Today. 2000 Aug;21(8):397-402 - PubMed
  143. Science. 1985 Dec 6;230(4730):1132-9 - PubMed
  144. Mini Rev Med Chem. 2001 May;1(1):5-16 - PubMed
  145. Receptor. 1994 Summer;4(2):93-108 - PubMed
  146. Cancer Res. 1998 Jul 1;58(13):2825-31 - PubMed
  147. Semin Oncol. 2001 Oct;28(5 Suppl 16):4-11 - PubMed
  148. Semin Oncol. 1999 Dec;26(6):683-90 - PubMed
  149. Curr Opin Biotechnol. 2009 Dec;20(6):692-9 - PubMed
  150. Crit Rev Oncol Hematol. 2005 Apr;54(1):11-29 - PubMed
  151. J Clin Immunol. 1991 May;11(3):117-27 - PubMed
  152. Science. 1986 Jun 27;232(4758):1644-6 - PubMed
  153. J Biol Chem. 1995 Jul 28;270(30):18067-76 - PubMed
  154. J Biol Chem. 2004 Feb 27;279(9):8269-77 - PubMed
  155. Trends Pharmacol Sci. 1994 Apr;15(4):124-9 - PubMed
  156. Toxicology. 1995 Dec 20;105(1):7-22 - PubMed
  157. Proteins. 2005 Jan 1;58(1):222-34 - PubMed
  158. Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6444-8 - PubMed
  159. Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):969-73 - PubMed
  160. Oncogene. 1990 Apr;5(4):489-95 - PubMed
  161. Nat Biotechnol. 2000 Feb;18(2):194-8 - PubMed
  162. Gene. 1993 Dec 27;137(1):51-6 - PubMed
  163. Cancer Res. 1985 Feb;45(2):879-85 - PubMed
  164. Cancer Res. 2005 Aug 1;65(15):6891-900 - PubMed
  165. Curr Opin Biotechnol. 1998 Aug;9(4):395-402 - PubMed
  166. Cancer Res. 2007 Jan 1;67(1):202-8 - PubMed
  167. J Biol Chem. 1989 Jan 5;264(1):259-65 - PubMed
  168. Cell Mol Biol (Noisy-le-grand). 2003 Mar;49(2):209-16 - PubMed
  169. Proc Natl Acad Sci U S A. 1986 Sep;83(17):6578-82 - PubMed
  170. Nucl Med Biol. 2007 Oct;34(7):757-78 - PubMed
  171. J Mol Med (Berl). 1999 Oct;77(10):699-712 - PubMed
  172. Curr Opin Mol Ther. 2010 Jun;12(3):340-9 - PubMed
  173. Proc Natl Acad Sci U S A. 1989 Jul;86(14):5537-41 - PubMed

Publication Types

Grant support